The prognostic importance of nuclear factor κb and hypoxia-inducible factor 1α in relation to the breast cancer subtype and the overall survival

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 6, 2014, Pages 464-470

  Rajković Molek, Koraljka ^a   Mustać, Elvira ^b   Hadžisejdić, Ita ^b   Jonjić, Nives ^b  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Breast cancer subtypes; Hypoxia inducible factor 1 ; Immunohistochemistry; Nuclear factor B; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; HIF1A PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; ENZYME ACTIVATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NF-KAPPA B; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84904214965     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31829271ce     Document Type: Article

References (31)

1. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypesdealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-1747.
2. Harbeck N, Thomssen CA. New look at node-negative breast cancer. Oncologist. 2010;15:29-38.
3. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17: 245-262.
4. Gosh S, Karin M. Missing pieces in the NF-kB puzzle. Cell. 2002;109:81-96.
5. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem. 2010;336:25-37.
6. Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2: 301-310.
7. Vordermark D. Hypoxia specific targets in cancer therapy: role of slice variants. BMC Med. 2010;12:1-3.
8. Dales JP, Beaufils N, Silvy M, et al. Hypoxia inducible factor 1a gene (HIF-1a) splice variants: potential prognostic biomarkers in breast cancer. BMC Med. 2010;8:44.
9. DorXević G, Matušan-Ilijaš K, Babarović E, et al. Hypoxia inducible factor 1a correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell carcinoma. J Exp Clin Cancer Res. 2009;20:40.
10. Cao Y, Karin M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2003;8: 215-223.
11. Lerebours F, Vacher S, Andrieu C, et al. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer. 2008; 8:41.
12. Gordon AH, O'Keefe RJ, Schwarz EM, et al. Nuclear factorkappaB- dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone. Cancer Res. 2005;65:3209-3217.
13. Hyseni A, van der Groep P, van der Vall E, et al. Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1a expression. Cell Oncol. 2011;34:565-570.
14. Vleugel MM, Greijer AE, Schwarts A, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1a expression in invasive breast cancer. J Clin Pathol. 2005;58:172-177.
15. Tavassoli FA, Devilee P. Pathology and Genetics: Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours. Lyon: IARC press; 2003.
16. Ellis IO, Galea M, Broughton N, et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992;20:479-489.
17. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56:37-47.
18. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28:2784-2795.
19. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-752.
20. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
21. Dent R, Trudeau M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
22. Reis-Filho JS, Tutt AN. Triple negative tumours. A critical review. Histopathology. 2008;52:108-118.
23. Gilmore TD. The Re1/NF-kappa B/I kappa B signal transduction pathway and cancer. Cancer Treat Res. 2003;115:241-265.
24. Vermeulen L, De Wilde G, Notebaert S, et al. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol. 2002;64:963-970.
25. Biswas DK, Singh S, Shi Q, et al. Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE. 2005;288:pe27.
26. Frasor J, Weaver A, Pradhan M, et al. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res. 2009;23:8918-8925.
27. Joyce D, Albanese C, Steer J, et al. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001;12:73-90.
28. Chaturvedi MM, Sung B, Yadav VR, et al. NF-kB addiction and its role in cancer: 'one size does not fit all'. Oncogene. 2011;30: 1615-1630.
29. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006;13:759-772.
30. Van Uden P, Kenneth NS, Rocha S. Regulation of hypoxiainducible factor-1alpha by NF-kappaB. Biochem J. 2008;412: 477-484.
31. Dales JP, Garcia S, Meunier-Carpentier S, et al. Overexpression of hypoxia-inducible factor HIF-1a predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer. 2005;116:734-739.